Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT03941860 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Lenalidomide With or Without Ixazomib in Treating Patients With Evidence of Residual Multiple Myeloma After Stem Cell Transplant

Start date: May 29, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplant. Immunotherapy with lenalidomide may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplant.

NCT ID: NCT03940833 Recruiting - Multiple Myeloma Clinical Trials

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Start date: May 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.

NCT ID: NCT03937635 Recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Start date: April 30, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide and dexamethasone works with or without daratumumab in treating patients with high-risk smoldering myeloma. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as daratumumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Giving lenalidomide and dexamethasone with daratumumab may work better in treating patients with smoldering myeloma.

NCT ID: NCT03934684 Not yet recruiting - Clinical trials for Relapsed Refractory Multiple Myeloma

Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma

Start date: July 28, 2019
Phase: Phase 4
Study type: Interventional

To characterize safety associated with the use of Kyprolis under the locally approved label.

NCT ID: NCT03933735 Not yet recruiting - Multiple Myeloma Clinical Trials

A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: May 2019
Phase: Phase 1
Study type: Interventional

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or refractory MM who have received at least 3 prior lines of therapy. The study consists of 2 portions, a monotherapy dose escalation (Arm A) and a monotherapy dose expansion (Arm B). Arm A will evaluate the safety, tolerability, PK and PD profiles of escalating doses of single-agent TNB-383B ranging from 25 micrograms to 40 milligrams per dose, administered once every 3 weeks (Q3W), in approximately 24 subjects. Once the maximum tolerated dose (MTD) or recommended phase 2 dose, (RP2D) is identified in Arm A, Arm B will be initiated to further characterize the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the MTD/RP2D dose of TNB 383B monotherapy in approximately 48 subjects.

NCT ID: NCT03931421 Recruiting - Multiple Myeloma Clinical Trials

B Cell Maturation Antigen(BMCA)-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Start date: May 31, 2019
Phase: Phase 2
Study type: Interventional

It's a single arm, open label prospective study, in which the safety and efficacy of B Cell Maturation Antigen(BMCA)-targeted CAR-T thearpy are evaluated in refractory/relapsed multiple myeloma patients.

NCT ID: NCT03915184 Not yet recruiting - Multiple Myeloma Clinical Trials

Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma

Start date: August 1, 2019
Phase: Phase 1
Study type: Interventional

A phase 1b, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

NCT ID: NCT03910439 Not yet recruiting - Myeloma-Multiple Clinical Trials

Avelumab in Combination With Hypofractionated Radiotherapy in Patients With Relapsed Refractory Multiple Myeloma

Start date: May 24, 2019
Phase: Phase 2
Study type: Interventional

Background: Multiple myeloma is a cancer that forms from plasma cells which normally produce important immune response antibodies. It cannot be cured. Researchers hope the combination of radiation combined with the drug avelumab causes the immune system to kill myeloma cells more effectively. Objective: To see if avelumab given with radiation treatment helps treat multiple myeloma. Also to see if giving the treatments together is safe. Eligibility: People ages 18 and older with multiple myeloma that has come back after treatment and has spread to other parts of the body Design: Participants will be screened with: Medical history Physical exam Blood, urine, and heart tests Possible tumor biopsy Bone marrow testing: A needle will be stuck into the participant s hipbone to take out a small amount of marrow. PET/CT scan and MRI: Participants will lie in a machine that takes pictures of the body. Participants will get avelumab through an IV. An IV is a small plastic tube put into an arm vein. They will get avelumab every 2 weeks for 2 doses. Then they will get radiation each day for 5 days. They will continue to get avelumab every 2 weeks as long as they do not have bad side effects and the treatment is helping their disease. Participants will have blood and urine tests, bone marrow biopsies, scans, and X-rays repeated during the study. Participants will have a follow-up visit 30 days after their last treatment dose. Then they will have visits every 3 6 months for up to 5 years....

NCT ID: NCT03909412 Not yet recruiting - Multiple Myeloma Clinical Trials

Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma

CarMob
Start date: April 2019
Phase: Phase 1
Study type: Interventional

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and G-CSF

NCT ID: NCT03908138 Recruiting - Multiple Myeloma Clinical Trials

RDD Versus VDD Followed by ASCT in Newly Diagnosed Young Patients With Multiple Myeloma

Start date: March 30, 2019
Phase: Phase 4
Study type: Interventional

Multiple myeloma (MM) is a common malignant hematology disease. The development of proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs) significantly improved the survival of MM patients. However, ASCT therapy in young patients with MM is still important. IMiDs have multiple effects in MM therapy. Except for direct cytotoxicity, IMiDs also play a variety of immune regulatory roles. Lenalidomide, a kind of IMiDs, was usually used in the therapy of relapsed/refractory MM. The efficacy and safety of RDD (lenalidomide, pegylated liposomal doxorubicin, dexamethasone) followed by ASCT in newly diagnosed young patients with MM still needs to be further validated.